For the Record - Oct. 2, 2007
- Share via
Breast cancer drug: A story in Monday’s Health section stated that the medication raloxifene, or Evista, may soon be approved to help prevent breast cancer in high-risk women. In fact, Evista was approved Sept. 14 to reduce the risk of breast cancer in high-risk post-menopausal women and post-menopausal women with osteoporosis.
Sign up for Essential California
The most important California stories and recommendations in your inbox every morning.
You may occasionally receive promotional content from the Los Angeles Times.
